Regulatory Q&A Forum
Ask questions, share knowledge, and get help from the regulatory community
For foreign establishments intending to market medical devices in the United States, designating a U.S. Agent is a mandatory part of the annual establishment registration process. While this seems lik...
While specific pricing for a "Person Responsible for Regulatory Compliance (PRRC) as a Service" can vary significantly between providers, what are the key factors that manufacturers should understand ...
With the European Chemicals Agency (ECHA) increasing its focus on enforcement, including planned inspections in 2026, how should a non-EU manufacturer critically evaluate and select a REACH Only Repre...
I am unable to process this request as it is currently formulated. The provided topic is "How to find an EU Authorized Representative for CBAM compliance?", which relates to European Union regulation...
Given the FDA's implementation of mandatory registration and listing for cosmetic product facilities, foreign establishments are required to designate a U.S. Agent. While specific pricing is not publi...
As medical device manufacturers budget for their European market compliance activities, how should they analyze the factors that determine the cost of a "PRRC as a Service" provider? When evaluating p...
With ECHA's enforcement project (REF-14) signaling increased scrutiny on REACH compliance ahead of 2026, many non-EU manufacturers are re-evaluating their Only Representative (OR) arrangements. Simply...
For sponsors of Class II in vitro diagnostic (IVD) devices, how do FDA-designated Special Controls function as a critical regulatory roadmap beyond the General Controls applicable to all devices? For ...
With the implementation of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA), what are the specific responsibilities and qualifications of a U.S. Agent for foreign cosmetic facilities? For...
When planning for 2026, medical device manufacturers face the critical task of budgeting for the Person Responsible for Regulatory Compliance (PRRC) role, particularly when utilizing an external 'PRRC...
For non-EU manufacturers preparing for future chemical compliance deadlines, such as the ongoing requirements under EU REACH, selecting an Only Representative (OR) is a critical strategic decision, no...
For a novel Class II in vitro diagnostic (IVD) test system, how do FDA Special Controls, as outlined in both a specific product classification regulation and an associated guidance document, shape the...
How does FDA's guidance, "Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions," influence the risk management and documentation strategy for a connecte...
When planning for the 2026 fiscal year, how can a medical device manufacturer, especially a small to medium-sized enterprise (SME) without an in-house expert, create a realistic and comprehensive budg...
For non-U.S. based medical device manufacturers planning to enter the U.S. market, appointing a U.S. Agent is a mandatory regulatory step. Beyond simply having a physical address in the United States,...
For connected medical devices, how should sponsors approach cybersecurity documentation within a premarket submission to meet current FDA expectations? While specific requirements depend on the device...
As medical device manufacturers prepare for evolving WEEE and EPR regulations targeting 2026, selecting the right compliance partner is a critical strategic decision. Beyond simple registration, how c...
As international biocompatibility standards like the ISO 10993 series continue to evolve, how should medical device manufacturers proactively adapt their evaluation strategies to ensure ongoing compli...
When a foreign medical device establishment plans to market its products in the United States, designating a U.S. Agent is a mandatory regulatory requirement. But what are the core responsibilities of...
For a US-based manufacturer of a regulated medical device, such as a Class II pharmacogenetic assessment system defined under 21 CFR 862.3364, expanding into the European market involves navigating di...